Radiopharm Theranostics Limited: Strong Interim Results from RAD101 Imaging Trial
Radiopharm Theranostics Limited (ASX: RAD) has reported encouraging interim results from its Phase 2b clinical trial evaluating RAD101, a novel imaging agent for brain metastases. The second interim analysis showed that 90% of evaluable patients had consistent findings between PET scans and MRI results, thereby meeting the study’s primary endpoint. The data also indicated strong and selective tumour uptake, highlighting RAD101’s ability to detect metabolic activity where traditional imaging methods may be inconclusive.
Early findings from a subset of patients further suggest a positive trend in sensitivity and specificity, reinforcing the agent’s diagnostic potential. RAD101 targets fatty acid synthase, a protein commonly overexpressed in solid tumours, supporting improved detection accuracy in complex neuro-oncology cases. With FDA Fast Track designation already secured, the company is progressing toward final data readout and potential advancement into pivotal trials, positioning RAD101 as a promising solution for more precise and timely diagnosis of brain metastases.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Radiopharm Theranostics Limited: Strong Interim Results from RAD101 Imaging Trial
Radiopharm Theranostics Limited (ASX: RAD) has reported encouraging interim results from its Phase 2b clinical trial evaluating RAD101, a novel imaging agent for brain metastases. The second interim analysis showed that 90% of evaluable patients had consistent findings between PET scans and MRI results, thereby meeting the study’s primary endpoint. The data also indicated strong and selective tumour uptake, highlighting RAD101’s ability to detect metabolic activity where traditional imaging methods may be inconclusive.
Early findings from a subset of patients further suggest a positive trend in sensitivity and specificity, reinforcing the agent’s diagnostic potential. RAD101 targets fatty acid synthase, a protein commonly overexpressed in solid tumours, supporting improved detection accuracy in complex neuro-oncology cases. With FDA Fast Track designation already secured, the company is progressing toward final data readout and potential advancement into pivotal trials, positioning RAD101 as a promising solution for more precise and timely diagnosis of brain metastases.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au